e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Shashikant Srivastava, Tawanda Gumbo
Source:
Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Journal Issue:
April
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Shashikant Srivastava, Tawanda Gumbo. Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis. Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Expert interview: Microbiologists on tuberculosis diagnostics
Related content which might interest you:
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013
Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2014; 43: 884-897
Year: 2014
Mefloquine as a potential drug against multidrug-resistant tuberculosis
Source: Eur Respir J 2015; 46: 1503-1505
Year: 2015
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017
Year: 2017
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4) 1700173; DOI: 10.1183/13993003.00173-2017
Year: 2017
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Linezolid in multidrug-resistant tuberculosis treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 485s
Year: 2004
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis
Source: Eur Respir J 2015; 46: 444-455
Year: 2015
Fluoroquinolone resistance in multidrug-resistant
Mycobacterium tuberculosis
independent of fluoroquinolone use
Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017
Year: 2017
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
Source: Eur Respir J 2013; 42: 156-168
Year: 2013
Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance
Source: Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017
Year: 2017
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Source: Eur Respir J 2013; 42: 1614-1621
Year: 2013
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis
Source: Eur Respir J 2016; 47: 1229-1234
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept